Evotec (EVT) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
16 Sep, 2026Initial reflections and organizational strengths
Scientific expertise and breadth of knowledge are key differentiators, offering a wide range of services.
The company's story and value proposition are complex, requiring clearer market communication.
An outside-in perspective enables objective questioning and process simplification.
Transparent internal dialogue is used to drive future performance.
Market environment and customer sentiment
Sector funding is improving, especially in later-stage pipeline investments, boosting market confidence.
Commercial indicators, including year-on-year sales, show positive momentum.
Customers are cautiously optimistic, focusing investments for maximum returns.
Horizon transformation program
Horizon targets €75 million in savings, with 20–30% impact expected in 2026.
Initiatives include site consolidation, centers of expertise, commercial investment, and process simplification.
The program aims to create a stable, growth-oriented platform beyond cost savings.
Latest events from Evotec
- Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026.EVT
Q2 2026 - Accelerating growth with innovation, cost savings, and a high-value asset pipeline.EVT
Company presentation - 2026 outlook cut as partnership delays weigh, but core business segments show strong momentum.EVT
Q2 2026 TU - Annual meeting to elect Trustees, review governance, and address audit and risk oversight.EVT
Proxy filing - Operational excellence, pipeline growth, and asset-light strategy drive sustainable value creation.EVT
Company presentation - Biologics growth, cost savings, and Horizon transformation drive high-end 2025 results.EVT
Q4 2025 - Biologics growth and €40m cost savings offset R&D decline, supporting 2024 guidance.EVT
Q3 2024 - Revenue up 2%, but losses deepened and restructuring accelerated in H1 2024.EVT
Q2 2024 - Revenue fell 4% but Biologics grew 10–11%, with guidance and cost savings reaffirmed.EVT
Q1 2025